Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer - PubMed (original) (raw)
. 2014 Oct;74(14):1452-61.
doi: 10.1002/pros.22862. Epub 2014 Aug 11.
Affiliations
- PMID: 25111810
- DOI: 10.1002/pros.22862
Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer
Nora Ness et al. Prostate. 2014 Oct.
Abstract
Backgrounds: The adaptive immune system can potentially have dual roles in cancer development and progression by contributing to or suppressing tumor progression and metastasis. The aim of this study was to evaluate the prognostic impact of adaptive immune cells residing in different tumor compartments in prostate cancer.
Methods: Tissue microarrays from 535 patients were constructed from viable and representative tumor epithelial and stromal areas of primary PC tumors, as well as from normal epithelial and stromal areas. Immunohistochemistry was used to evaluate the density of CD3+, CD4+, CD8+, and CD20+ lymphocytes in both tumor epithelial and tumor stromal areas.
Results: In univariate analysis, a high density of CD3+ (P = 0.037) and CD8+ lymphocytes (P = 0.010) in tumor epithelial areas was associated with significantly shorter biochemical failure-free survival. When analyzing both tumor epithelial and stromal tissue compartments as one entity, similar relationships were observed for CD3+ (P = 0.046), CD4+ (P = 0.026), and CD8+ (P = 0.003) lymphocytes. In multivariate analysis, high densities of CD8+ lymphocytes limited to tumor epithelial areas (HR = 1.45, P = 0.032), as well as in the total tumor tissue (HR = 1.57, P = 0.007), were independent negative prognostic factors for biochemical failure-free survival.
Conclusions: A high density of CD8+ lymphocytes, especially in tumor epithelial areas, is an independent negative prognostic factor for biochemical failure-free survival.
Keywords: B lymphocytes; CD3+; CD8+; T lymphocytes; prostate carcinoma.
© 2014 Wiley Periodicals, Inc.
Similar articles
- Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Al-Shibli KI, et al. Clin Cancer Res. 2008 Aug 15;14(16):5220-7. doi: 10.1158/1078-0432.CCR-08-0133. Clin Cancer Res. 2008. PMID: 18698040 - Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.
de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H, Nijman HW. de Jong RA, et al. Gynecol Oncol. 2009 Jul;114(1):105-10. doi: 10.1016/j.ygyno.2009.03.022. Epub 2009 May 2. Gynecol Oncol. 2009. PMID: 19411095 - Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.
Kärjä V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R. Kärjä V, et al. Anticancer Res. 2005 Nov-Dec;25(6C):4435-8. Anticancer Res. 2005. PMID: 16334122 - CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM. Rathore AS, et al. Indian J Med Res. 2014 Sep;140(3):361-9. Indian J Med Res. 2014. PMID: 25366203 Free PMC article. - The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma.
Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT. Al-Shibli K, et al. APMIS. 2010 May;118(5):371-82. doi: 10.1111/j.1600-0463.2010.02609.x. APMIS. 2010. PMID: 20477813
Cited by
- Predicting prostate adenocarcinoma patients' survival and immune signature: a novel risk model based on telomere-related genes.
Zheng J, Chen J, Li H, Li Y, Dong W, Jiang X. Zheng J, et al. Discov Oncol. 2024 Jun 2;15(1):203. doi: 10.1007/s12672-024-00986-2. Discov Oncol. 2024. PMID: 38825615 Free PMC article. - Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression.
Sadasivan SM, Loveless IM, Chen Y, Gupta NS, Sanii R, Bobbitt KR, Chitale DA, Williamson SR, Rundle AG, Rybicki BA. Sadasivan SM, et al. Cancer Med. 2024 Mar;13(6):e7118. doi: 10.1002/cam4.7118. Cancer Med. 2024. PMID: 38523528 Free PMC article. - Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk.
Rasmussen M, Fredsøe J, Salachan PV, Blanke MPL, Larsen SH, Ulhøi BP, Jensen JB, Borre M, Sørensen KD. Rasmussen M, et al. NPJ Precis Oncol. 2024 Feb 23;8(1):48. doi: 10.1038/s41698-024-00540-x. NPJ Precis Oncol. 2024. PMID: 38395986 Free PMC article. - Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B, Zhang X, Zhu S, Wang C, Deng Z, Wang T, Wu Y. Hu B, et al. Eur J Med Res. 2024 Jan 31;29(1):92. doi: 10.1186/s40001-024-01672-3. Eur J Med Res. 2024. PMID: 38297388 Free PMC article. - Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer.
Séguier D, Adams ES, Kotamarti S, D'Anniballe V, Michael ZD, Deivasigamani S, Olivier J, Villers A, Hoimes C, Polascik TJ. Séguier D, et al. Nat Rev Urol. 2024 May;21(5):290-302. doi: 10.1038/s41585-023-00834-y. Epub 2023 Dec 19. Nat Rev Urol. 2024. PMID: 38114768 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials